Attached files

file filename
EX-99.1 - EX-99.1 - IMMUNE PHARMACEUTICALS INCexhibit1.htm






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):   May 20, 2013

EpiCept Corporation
(Exact name of registrant as specified in its charter)

Delaware 000-51290 52-1841431
(State or other jurisdiction
(I.R.S. Employer
of incorporation) File Number) Identification No.)
777 Old Saw Mill River Rd., Tarrytown, New York   10591
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:   914-606-3500

Not Applicable
Former name or former address, if changed since last report


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On May 20, 2013, EpiCept Corporation (the "Registrant") issued a press release announcing its operating and financial results for the quarter ended March 31, 2013. A copy of the press release is being furnished as Exhibit 99.1 to this Form 8-K.

This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

99.1 Press release of EpiCept Corporation, dated May 20, 2013, announcing the operating and financial results for the quarter ended March 31, 2013.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    EpiCept Corporation
May 20, 2013   By:   /s/ Robert W. Cook
        Name: Robert W. Cook
        Title: Interim Chief Executive Officer

Exhibit Index

Exhibit No.   Description

  Press release, dated May 20, 2013.